Endothelial  ||| S:0 E:12 ||| JJ
progenitor  ||| S:12 E:23 ||| JJ
cells  ||| S:23 E:29 ||| NNS
in  ||| S:29 E:32 ||| IN
pulmonary  ||| S:32 E:42 ||| JJ
hypertension  ||| S:42 E:55 ||| NN
-  ||| S:55 E:57 ||| :
dawn  ||| S:57 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
cell-based  ||| S:65 E:76 ||| JJ
therapy ||| S:76 E:83 ||| NN
?  ||| S:83 E:85 ||| .
There  ||| S:85 E:91 ||| EX
is  ||| S:91 E:94 ||| VBZ
mounting  ||| S:94 E:103 ||| VBG
interest  ||| S:103 E:112 ||| NN
in  ||| S:112 E:115 ||| IN
the  ||| S:115 E:119 ||| DT
concept  ||| S:119 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
endothelial  ||| S:130 E:142 ||| JJ
progenitor  ||| S:142 E:153 ||| JJ
cell  ||| S:153 E:158 ||| NN
( ||| S:158 E:159 ||| -LRB-
EPC ||| S:159 E:162 ||| NNP
)  ||| S:162 E:164 ||| -RRB-
therapy  ||| S:164 E:172 ||| NN
for  ||| S:172 E:176 ||| IN
the  ||| S:176 E:180 ||| DT
treatment  ||| S:180 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
pulmonary  ||| S:193 E:203 ||| FW
arterial  ||| S:203 E:212 ||| FW
hypertension  ||| S:212 E:225 ||| FW
( ||| S:225 E:226 ||| -LRB-
PAH ||| S:226 E:229 ||| NNP
) ||| S:229 E:230 ||| -RRB-
.  ||| S:230 E:232 ||| .
Recent  ||| S:232 E:239 ||| JJ
successful  ||| S:239 E:250 ||| JJ
pilot  ||| S:250 E:256 ||| NN
studies  ||| S:256 E:264 ||| NNS
in  ||| S:264 E:267 ||| IN
idiopathic  ||| S:267 E:278 ||| JJ
PAH  ||| S:278 E:282 ||| NNS
have  ||| S:282 E:287 ||| VBP
raised  ||| S:287 E:294 ||| VBN
questions  ||| S:294 E:304 ||| NNS
about  ||| S:304 E:310 ||| IN
the  ||| S:310 E:314 ||| DT
contribution  ||| S:314 E:327 ||| NN
of  ||| S:327 E:330 ||| IN
progenitor  ||| S:330 E:341 ||| JJ
cells  ||| S:341 E:347 ||| NNS
circulating  ||| S:347 E:359 ||| VBG
in  ||| S:359 E:362 ||| IN
the  ||| S:362 E:366 ||| DT
peripheral  ||| S:366 E:377 ||| JJ
blood  ||| S:377 E:383 ||| NN
to  ||| S:383 E:386 ||| TO
pulmonary  ||| S:386 E:396 ||| VB
vascular  ||| S:396 E:405 ||| JJ
homeostasis  ||| S:405 E:417 ||| NN
and  ||| S:417 E:421 ||| CC
to  ||| S:421 E:424 ||| TO
the  ||| S:424 E:428 ||| DT
process  ||| S:428 E:436 ||| NN
of  ||| S:436 E:439 ||| IN
vascular  ||| S:439 E:448 ||| JJ
remodelling ||| S:448 E:459 ||| NN
.  ||| S:459 E:461 ||| .
This  ||| S:461 E:466 ||| DT
review  ||| S:466 E:473 ||| NN
will  ||| S:473 E:478 ||| MD
summarise  ||| S:478 E:488 ||| VB
the  ||| S:488 E:492 ||| DT
work  ||| S:492 E:497 ||| NN
performed  ||| S:497 E:507 ||| VBN
to  ||| S:507 E:510 ||| TO
date  ||| S:510 E:515 ||| NN
in  ||| S:515 E:518 ||| IN
animal  ||| S:518 E:525 ||| NN
and  ||| S:525 E:529 ||| CC
human  ||| S:529 E:535 ||| JJ
therapeutic  ||| S:535 E:547 ||| JJ
trials  ||| S:547 E:554 ||| NNS
and  ||| S:554 E:558 ||| CC
clarify  ||| S:558 E:566 ||| VB
what  ||| S:566 E:571 ||| WP
is  ||| S:571 E:574 ||| VBZ
known  ||| S:574 E:580 ||| VBN
about  ||| S:580 E:586 ||| IN
the  ||| S:586 E:590 ||| DT
potential  ||| S:590 E:600 ||| JJ
contribution  ||| S:600 E:613 ||| NN
of  ||| S:613 E:616 ||| IN
EPCs  ||| S:616 E:621 ||| JJ
to  ||| S:621 E:624 ||| TO
the  ||| S:624 E:628 ||| DT
pathophysiology  ||| S:628 E:644 ||| NN
of  ||| S:644 E:647 ||| IN
PAH ||| S:647 E:650 ||| NNP
.  ||| S:650 E:652 ||| .
